InvestorsHub Logo
Followers 195
Posts 24729
Boards Moderated 0
Alias Born 04/03/2010

Re: fluteman post# 677410

Friday, 03/08/2024 6:11:21 PM

Friday, March 08, 2024 6:11:21 PM

Post# of 703867
They didn't really hide it. Just have to look for it. It was/is a trial, not one drug or even a new drug necessarily.

Group Leader: Dr Paul Mulholland

Consultant in Medical Oncology and Honorary Associate Professor
Email: p.mulholland@ucl.ac.uk
Group members
Dr Diego Ottaviani
NIHR Academic Clinical Fellow & Consultant in Medical Oncology
Dr Nick Brown
Clinical Research Fellow & Specialist Registrar in Medical Oncology
Dr Ben Kinnersley
Senior Research Fellow - Senior Computational Biologist
Dr Vassilis Genoud
Senior Clinical Fellow
Dr Ariel Finkielsztein
Senior Research Fellow
Max Reinstein
iBSc student

Research

Glioblastoma is the most common and aggressive primary malignant brain tumour. Due to the lack of effective treatment options, Cancer Research UK has included glioblastoma in the category of ‘cancers of substantial unmet need’. Our goal is to improve clinical outcomes for patients with glioblastoma, from pre-clinical development of novel therapies to early and later phase clinical trials.

Clinical trials

We have set up a national programme of immunotherapy clinical trials for patients with glioblastoma. We have recently completed recruitment for the IPI-GLIO trial (ISRCTN84434175) which is a phase II, open label, randomized study of ipilimumab (anti-CTLA monoclonal antibody) and temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma. We are currently actively developing new clinical trials.

Molecular mechanisms in glioblastoma

Alongside clinical trials, we are running a translational programme to improve our understanding of the molecular mechanisms driving glioblastoma response and resistance to treatment. There is emerging evidence that DNA organisation is critical in mediating responses to cancer treatment including chemotherapy and immunotherapy. We are characterising the DNA architecture in glioblastoma and how it can be modified to enhance treatment efficacy.



https://www.ucl.ac.uk/cancer/research/department-oncology/glioblastoma-research-group

I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News